Relationship Between Esophageal Disease and Pulmonary Fibrosis
Digestive Diseases and Sciences · 2023-04 · 68 (4) · 1096-1105
DOI: 10.1007/s10620-023-07908-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Digestive Diseases and Sciences, online erschienen am 14.03.2023. Verfasst von Joyce C Zhou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Gastroesophageal Reflux, Idiopathic Pulmonary Fibrosis, Esophagitis, Peptic. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 65 Literaturangaben.
Abstract (Originalsprache)
Esophageal disorders are prevalent among patients with chronic lung diseases, including idiopathic pulmonary fibrosis (IPF). Gastroesophageal reflux disease (GERD) has been associated with IPF prevalence, severity, and respiratory decline. The pathophysiologic relationship between GERD and IPF is likely bidirectional, with aspiration of refluxate leading to lung inflammation and fibrosis, while the restrictive pulmonary physiology may contribute to altered transdiaphragmatic pressure gradient and increased reflux. Esophageal symptoms are frequently absent and do not predict esophageal dysfunction or pathologic reflux in patients with IPF, and objective diagnostic tools including upper endoscopy, ambulatory reflux monitoring, and high-resolution manometry are often needed. Impedance-based testing that identifies both weakly/non-acidic and acid reflux may provide important additional diagnostic value beyond pH-based acid testing alone. Novel metrics and maneuvers, including advanced impedance measures on impedance-pH study and provocative testing on HRM, may hold promise to future diagnostic advancements. The main treatment options include medical therapy with acid suppressants and anti-reflux surgery, although their potential benefits in pulmonary outcomes of IPF require further validations. Future directions of research include identifying phenotypes of IPF patients who may benefit from esophageal testing and treatment, determining the optimal testing strategy and protocol, and prospectively assessing the value of different esophageal therapies to improve outcomes while minimizing risks. This review will discuss the pathophysiology, evaluation, and management of esophageal diseases, particularly GERD, in patients with IPF, as informed by the most recent publications in the field, in hopes of identifying targets for future study and research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.
- Harvard Medical School, Boston, MA, USA.
- Division of Digestive and Liver Diseases, The University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Harvard Medical School, Boston, MA, USA. wwchan@bwh.harvard.edu.
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA. wwchan@bwh.harvard.edu.
- Division of Gastroenterology, Hepatology and Endoscopy, Brigham and Women's Hospital, 75 Francis Street, Boston, MA, 02115, USA.
Zitieren
APA
Zhou, J. C., Gavini, S., Chan, W. W., & Lo, W. K. (2023). Relationship Between Esophageal Disease and Pulmonary Fibrosis. Digestive Diseases and Sciences, 68(4), 1096-1105. https://doi.org/10.1007/s10620-023-07908-2
Vancouver
Zhou JC, Gavini S, Chan WW, Lo WK. Relationship Between Esophageal Disease and Pulmonary Fibrosis. Digestive Diseases and Sciences. 2023;68(4):1096-1105. doi:10.1007/s10620-023-07908-2
BibTeX
@article{Zhou2023,
author = {Zhou, Joyce C and Gavini, Sravanya and Chan, Walter W and Lo, Wai-Kit},
title = {Relationship Between Esophageal Disease and Pulmonary Fibrosis},
journal = {Digestive Diseases and Sciences},
year = {2023},
volume = {68},
number = {4},
pages = {1096--1105},
doi = {10.1007/s10620-023-07908-2}
}
EUVIMED